Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial

Lancet

Volumn 366, Issue 9493, 2005, Pages 1279-1289

  Dormandy, John A ^a   Charbonnel, Bernard ^b   Eckland, David J A ^c   Erdmann, Erland ^d   Massi Benedetti, Massimo ^e   Moules, Ian K ^f   Skene, Allan M ^g   Tan, Meng H ^h   Lefèbvre, Pierre J ⁱ   Murray, Gordon D ^j   Standl, Eberhard ^k   Wilcox, Robert G ^l   Wilhelmsen, Lars ^m   Betteridge, John ⁿ   Birkeland, Kåre ^o   Golay, Alain ^p   Heine, Robert J ^q   Korányi, László ^c   Laakso, Markku ^r   Mokáň, Marián ^s   Norkus, Antanas ^t   Pirags, Valdis ^u   Podar, Toomas ^v   Scheen, André ^w   Scherbaum, Werner ^x   Schernthaner, Guntram ^y   Schmitz, Ole ^z   Škrha, Jan ^aa   Smith, Ulf ^m   Tatoň, Jan ^ab   more..

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b Clinique d'Endocrinologie Hotel Dieu CHU de Nantes   (France)

^c University of Cologne ^*  (Hungary)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF PERUGIA   (Italy)

^f Takeda Europe R and D Centre   (United Kingdom)

^g Nottingham Clinical Research Group   (United Kingdom)

^h ELI LILLY AND COMPANY   (United States)

ⁱ CHU SART TILMAN   (Belgium)

^j UNIVERSITY OF EDINBURGH   (United Kingdom)

^k INSTITUT FÜR DIABETESFORSCHUNG   (Germany)

^l NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^m UNIVERSITY OF GOTHENBURG   (Sweden)

ⁿ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^o AKER UNIVERSITY HOSPITAL   (Norway)

^p GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^q VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^r KUOPIO UNIVERSITY HOSPITAL   (Finland)

^s University Teaching Hospital in Martin   (Slovakia)

^t KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

^u PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^v Endocrinology Centre   (Estonia)

^w UNIVERSITY OF LIÈGE   (Belgium)

^x HEINRICH HEINE UNIVERSITY   (Germany)

^y KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^z AARHUS UNIVERSITY   (Denmark)

^aa Czech Zoological Society   (Czech Republic)

^ab MEDICAL UNIVERSITY OF WARSAW   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; METFORMIN; NITRATE; PIOGLITAZONE; PLACEBO; SULFONYLUREA; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANGINA PECTORIS; ANKLE; ARTICLE; BLADDER CANCER; BREAST CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; COLON CANCER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENDOVASCULAR SURGERY; FATALITY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; LEG AMPUTATION; LEG ARTERY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PNEUMONIA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; REGISTER; SILENT MYOCARDIAL INFARCTION; STANDARD; STROKE; TIME; TITRIMETRY; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PPAR GAMMA; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 26244453309     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)67528-9     Document Type: Article

References (18)

1. NA Roper, RW Bilous, WF Kelly Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study BMJ 322 2001 1389 1393
2. J Stamler, O Vaccaro, JD Newton Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Interventional trial Diabetes Care 16 1993 434 444
3. K-T Khaw, N Wareham, R Luben Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) BMJ 322 2001 15 18
4. SM Haffner, S Lehto, T Ronnemaa, K Pyorala, M Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
5. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial Lancet 361 2003 2005 2016
6. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
7. H Yki-Jarvinen Drug therapy: thiazolidinediones N Engl J Med 351 2004 1106 1118
8. A Pf̊tzner, N Marx, G L̊bben Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the Pioneer study J Am Coll Cardiol 45 2005 1925 1931
9. B Charbonnel, J Dormandy, E Erdmann, M Massi-Benedetti, A Skene The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients Diabetes Care 27 2004 1647 1653
10. A desktop guide to type 2 diabetes mellitus: European Diabetes Policy Group 1999 Diabet Med 16 1999 716 730
11. KKG Lan, DL Demets Group sequential procedures: calendar versus information time Stat Med 8 1989 1191 1198
12. P Grambsch, T Thernau Proportional hazards tests and diagnostics based on weighted residuals Biometrica 81 1994 515 526
13. R Goldberg, D Kendall, M Deeg A comparison of lipid and glycaemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 28 2005 1547 1554
14. GM Reaven Banting lecture 1988: role of insulin resistance in human disease Diabetes 37 1988 1595 1607
15. B Charbonnel, M Roden, R Urquhart Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens Diabetologia 48 2005 553 560
16. US Department of Health and Human Services, National Institute of Diabetes and Digestive and Kidney Diseases Tight glucose control lowers CVD by about 50 percent in diabetes NIH News June 2005 12
17. MN Feinglos, MA Bethel Therapy of type 2 diabetes, cardiovascular death, and the UGDP Am Heart J 138 1999 S346 S352
18. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853